Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers

Clinical trials repurposing peroxisome proliferator-activated receptor-gamma (PPARγ) agonists as anticancer agents have exhibited lackluster efficacy across a variety of tumor types. Here, we report that increased PPARG expression is associated with a better prognosis but is anticorrelated with hist...

Descripción completa

Detalles Bibliográficos
Autores principales: Loo, Ser Yue, Syn, Nicholas L., Koh, Angele Pei-Fern, Teng, Janet Cheng-Fei, Deivasigamani, Amudha, Tan, Tuan Zea, Thike, Aye Aye, Vali, Shireen, Kapoor, Shweta, Wang, Xiaoyuan, Wang, Jiong Wei, Tan, Puay Hoon, Yip, George W., Sethi, Gautam, Huang, Ruby Yun-Ju, Hui, Kam Man, Wang, Lingzhi, Goh, Boon Cher, Kumar, Alan Prem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476547/
https://www.ncbi.nlm.nih.gov/pubmed/34580286
http://dx.doi.org/10.1038/s41420-021-00635-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476547/
https://www.ncbi.nlm.nih.gov/pubmed/34580286
http://dx.doi.org/10.1038/s41420-021-00635-5

Ejemplares similares